Company: HUM
Filing Date: 2025-03-07
Form Type: DEF 14A
Source: 0001193125-25-048976
Chunk: 43

Company: HUMANA INC
Filing Date: 2025-03-07
Form: DEF 14A
Chunk 43
---
 M.D.                                               |     |   3,511 |
| George Renaudin II                                                   |     |   5,096 |
| All executive officers as a group (11 in number, including our NEOs) |     | 218,753 |

| Raquel C. Bono, M.D.       |     |  1,663 |
| Frank A. D’Amelio          |     | 28,062 |
| David T. Feinberg, M.D.    |     |  1,254 |
| Wayne A.I. Frederick, M.D. |     |  1,663 |
| John W. Garratt            |     |    382 |
| Kurt J. Hilzinger          |     | 40,304 |
| Karen W. Katz              |     |  2,688 |
| Marcy S. Klevorn           |     |  1,247 |
| Brad D. Smith              |     |  1,601 |

| (f) | Does not include the January 2, 2025 annual stock retainer of 783 restricted stock units granted to each of our directors (other than Mr. Rechtin) pursuant to our 2024 director compensation program, which restricted stock units are expected to vest in full on December 31, 2025. The restricted stock units represent approximately $200,000 and were determined using the grant date fair market value of our common stock $255.54. |

| (2) | As of March 1, 2025, no Shares are pledged by any of our executive officers or directors in accordance with our policy prohibiting pledging or hedging transactions. |

| (3) | Based on 120,641,615 Shares outstanding as of December 31, 2024. Unless indicated, ownership is less than 1% of the class. |

| Stock Ownership Information • 2025 Proxy Statement | Humana |     | 43 |

Compensation Discussion and Analysis This Compensation Discussion and Analysis (CD&A) presents in detail our executive compensation policies and practices, describing each element of compensation and the decision-making process by our Organization & Compensation Committee (“Committee”) that supports it. We encourage you to read this CD&A in conjunction with the compensation tables that follow for additional context to the Committee’s decisions with respect to the 2024 compensation of our Named Executive Officers (“NEOs”), as listed below.

|